2000年至2021年期间在芬兰诊断出多发性骨髓瘤患者的并发症和生存率
Kai Kysenius1, Anna Anttalainen2, Iiro Toppila2
1Medaffcon Oy, Espoo, Finland. kai.kysenius@medaffcon.fi.
Annals of hematology
|July 4, 2024
概括
多发性骨髓瘤 (MM) 发病率在芬兰翻了一番,但生存率有了显著的改善,特别是自主干细胞移植 (ASCT). MM患者经历了更多的并发症和更高的医疗保健资源利用率 (HCRU).
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 多发性骨髓瘤 (MM) 尽管有治疗进展,但仍然无法治愈.
- 现实世界的证据 (RWE) 对于了解MM患者的结果至关重要.
- 了解MM发病率,生存率和医疗保健需求至关重要.
研究的目的:
- 分析芬兰成年MM患者的患者特征,发病率,存活率,并发症和医疗资源利用率 (HCRU).
- 评估2000年至2021年MM发病率和整体存活率 (OS) 的趋势.
- 为了比较接受自主干细胞移植 (ASCT) 和没有接受的MM患者之间的结果.
主要方法:
- 全国回顾性现实世界证据 (RWE) 研究.
- 包括7070名在2000-2021年期间被诊断为MM的成年MM患者.
- 与21,210个年龄,性别和地区匹配的对照进行了比较.
主要成果:
- 每10万人口中的MM发病率从4.11增加到8.33;年龄标准化发病率从2.51增加到3.53.
- 在MM患者中,总生存时间 (mOS) 的中位数从2.8年 (2000-2004) 增加到4.4年 (2017-2021).
- 在ASCT接受者 (9.2年) 和非接受者 (2.7年) 之间,mOS显著更高.
- 与对照组相比,MM患者表现出更多的并发症和更高的HCRU.
结论:
- MM发病率有所增加,特别是在老年人群中,这表明诊断有所改善.
- 治疗的进步导致芬兰MM患者的生存结果显著改善.
- 在MM患者中,ASCT与显著延长的生存时间有关.
- MM患者需要更多的医疗保健资源,并承担更高的并发症负担.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340
01:20Comparing the Survival Analysis of Two or More Groups
175
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
175
01:24Kaplan-Meier Approach
123
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
123
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:15Assumptions of Survival Analysis
121
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
121
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K